|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Exploring the Latest Advances in Advanced Prostate Cancer Treatment
|
Oliver Sartor, MD
Alicia Morgans and Oliver Sartor discuss the latest developments and changes in the advanced prostate cancer landscape. Dr. Sartor mentions that novel hormones are used as first-line treatment in most cases and that the controversy around treating first-line metastatic CRPC is no longer relevant. |
|
|
|
|
|
|
|
|
|
|
| Testosterone Recovery in Patients With Prostate Cancer |
Tanya Dorff, MD
Tanya Dorff and Alicia Morgans discuss testosterone suppression and recovery in prostate cancer patients. Dr. Dorff emphasizes the importance of discussing this data when talking to our patients about side effects of ADT, how long they may last, and will they recover their testosterone, and if so, when? |
|
|
|
|
|
|
|
|
|
|
|
Challenges, Controversies, and Opportunities of PARP Inhibitor Combinations with Androgen Receptor Signaling Inhibitors
|
Kim Chi, MD
In this discussion between Alicia Morgans and Kim Chi, they discuss the challenges, controversies, and opportunities of PARP inhibitor combinations with androgen receptor signaling inhibitors.
|
|
|
|
|
|
|
|
|
|
|
| PSMAfore: A Phase 3 Study To Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer
|
| A. Oliver Sartor MD
|
| The phase 2 TheraP and phase 3 VISION trials demonstrated that 177Lu-PSMA-617 can prolong rPFS and OS in patients with mCRPC who have previously received multiple lines of therapy. However, the role of 177Lu-PSMA-617 earlier in the treatment trajectory is still unclear. The PSMAfore trial aims to investigate the effect of 177Lu-PSMA-617 or a change in ARPI on rPFS in taxane-naïve patients with mCRPC. |
|
|
|
|
|
| Burning Questions in Oncological Urology: The Current and Future Role of PSMA-Based Theranostics in Men with Advanced Prostate Cancer
|
| Silke Gillessen Sommer, MD,
|
| Silke Gillessen Sommer discusses the current and future role of PSMA-based theranostics in men with advanced prostate cancer. Professor Gillessen began by noting that theranostics entails treating the “right” patient by image selection. This requires an appropriate cell surface target, with corresponding ligands, linkers, and isotopes.
|
|
|
|
|
|
|
|
|
|
|
| A Phase I/II Dose-Escalation Study of Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA
|
| Jones Nauseef, MD, Ph.D.
|
| Jones Nauseef discusses the trial design of a phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive mCRPC in patients with prior treatment with 177Lu-PSMA. As PSMA targeted radiotherapy is now an active standard-of-care treatment in mCRPC, ongoing studies with alternative approaches to targeting PSMA will increasingly need to consider the consequences of sequential PSMA-targeted radiotherapy exposure. |
|
|
|
|
|
| Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE |
| Eleni Efstathiou, MD, Ph.D. |
| Eleni Efstathiou presents the second interim analysis of MAGNITUDE, which evaluates the combination of niraparib and abiraterone acetate/prednisone in patients with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. |
|
|
|
|
|
| PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2 |
| Elena Castro, MD, Ph.D. |
| Elena Castro provided a discussion of PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) immediately following the presentation of updated data from TRITON3 and TALAPRO-2. Dr. Castro offered support for the work both completed and ongoing and emphasized a few key points including, that the balance of potential benefits and side effects will be impacted by refined understanding of how ARPI and PARPi behave together. |
|
|
|
|
|
|
